These results support the conclusion that further preclinical studies are now needed to investigate the effect of PDK1/Aurora kinase inhibitors with improved pharmacokinetic properties and/or molecular bioavailability that might result in development of new treatments for pancreatic cancer. The gene discussed is PDK1; the disease is pancreatic neoplasm.